IBN (“InvestorBrandNetwork”), an innovative corporate communications firm and content distributor, today announced its collaboration with Kisaco Research for its upcoming Health Equity in Clinical Trials Congress, which is slated to take place at the beautiful Hilton Boston Back Bay on Feb. 22-23, 2023. Kisaco is a leader in combining state-of-the-art conference production with high-impact networking to drive conversations between marquee organizations, policymakers, academic institutions, medtech and biopharma companies. The upcoming event aims to help facilitate change for underrepresented communities through industry action and technology across the animal health, beauty, health and wellness, AI and tech, drug development, women’s health, legal compliance and regulatory sectors. As media sponsor for the event, IBN will leverage its wide array of extensive corporate communications solutions to heighten the visibility of conference organizers, speakers and participating organizations via a network of digital channels and full-scale media distribution. “Kisaco Research has built a reputation for facilitating high-powered networking and actionable change within growth-oriented areas. Our team always looks forward to collaborating on their events,” said Jonathan Keim, communications director for IBN. “We are utilizing the latest tools available in social media strategy and article syndication to maximize outreach.”
To view the full press release, visit https://ibn.fm/juDdw
About IBN
IBN (InvestorBrandNetwork) consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire (“IW”) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.